SV2001000202A - USE OF (-) - 5-CETO-2-N, N-D1-N-PROPYLAMINE-TETRAHYDROTETHRALINE FOR THE TREATMENT OF PARKINSON'S EVIL - Google Patents

USE OF (-) - 5-CETO-2-N, N-D1-N-PROPYLAMINE-TETRAHYDROTETHRALINE FOR THE TREATMENT OF PARKINSON'S EVIL

Info

Publication number
SV2001000202A
SV2001000202A SV2000000202A SV2000000202A SV2001000202A SV 2001000202 A SV2001000202 A SV 2001000202A SV 2000000202 A SV2000000202 A SV 2000000202A SV 2000000202 A SV2000000202 A SV 2000000202A SV 2001000202 A SV2001000202 A SV 2001000202A
Authority
SV
El Salvador
Prior art keywords
evil
parkinson
tetrahydrotethraline
ceto
propylamine
Prior art date
Application number
SV2000000202A
Other languages
Spanish (es)
Inventor
Durk Dijkstra
Leonard Theodore Meltzer
Bastiaan Johan Venhuis
Wikstrom Hakan Vilhelm
Lawrence David Wise
David Juergen Wustrow
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SV2001000202A publication Critical patent/SV2001000202A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EL MAL DE PARKINSON SE TRATA CON UN COMPUESTO DE LA FORMULA (VER FORMULA) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.PARKINSON'S EVIL IS TREATED WITH A COMPOUND OF THE FORMULA (SEE FORMULA) OR A PHARMACEUTICALLY ACCEPTABLE SALT.

SV2000000202A 1999-10-20 2000-10-16 USE OF (-) - 5-CETO-2-N, N-D1-N-PROPYLAMINE-TETRAHYDROTETHRALINE FOR THE TREATMENT OF PARKINSON'S EVIL SV2001000202A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16071699P 1999-10-20 1999-10-20

Publications (1)

Publication Number Publication Date
SV2001000202A true SV2001000202A (en) 2001-10-16

Family

ID=22578122

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000202A SV2001000202A (en) 1999-10-20 2000-10-16 USE OF (-) - 5-CETO-2-N, N-D1-N-PROPYLAMINE-TETRAHYDROTETHRALINE FOR THE TREATMENT OF PARKINSON'S EVIL

Country Status (8)

Country Link
AR (1) AR026086A1 (en)
AU (1) AU1209501A (en)
CO (1) CO5251402A1 (en)
GT (1) GT200000182A (en)
PA (1) PA8505301A1 (en)
PE (1) PE20010746A1 (en)
SV (1) SV2001000202A (en)
WO (1) WO2001028977A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001438D0 (en) * 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2065450A1 (en) * 1989-07-05 1991-01-06 James V. Peck Substituted 2-aminotetralins
US6187808B1 (en) * 1998-07-28 2001-02-13 Warner-Lambert Company Hexahydro-naphthalenone oximes and hydrazones

Also Published As

Publication number Publication date
AR026086A1 (en) 2002-12-26
CO5251402A1 (en) 2003-02-28
AU1209501A (en) 2001-04-30
PA8505301A1 (en) 2002-12-30
GT200000182A (en) 2002-04-12
PE20010746A1 (en) 2001-07-27
WO2001028977A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
EA200300717A1 (en) Heterocyclylindazole and azazin-dazole compounds as 5-hydroxytriptamine-6-ligands
BR0109703A (en) Piperazine Derivatives
MY143203A (en) Novel compounds having inhibitory activity against sodium-dependent transporter
EA200200571A1 (en) NEW COMPOSITION AND ITS APPLICATION
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
PT1193270E (en) PYRROLOBENZODIAZEPINAS
DE60216233D1 (en) Carbolinderivate
MX9305248A (en) DIARILPIPERAZINOACETAMIDA COMPOUNDS.
ES2157252T3 (en) APPLICATION OF RILUZOL IN THE TREATMENT OF NEURO-AIDS.
EA200300716A1 (en) HETEROCYCLILALKILINDOL OR-ASAINDOL COMPOUNDS AS LIGAND 5-HYDROXYTRIPTAMINE-6
MXPA02012076A (en) Chemical compounds.
AU2001266575A1 (en) Chemical compounds
TR200201245T2 (en) Oncolytic combinations for cancer treatment.
BR0107628A (en) 1,2-diarylbenzimidazoles for treating diseases that are associated with microglial activation
DE60112960D1 (en) CONDENSED PYRIDOINDOL DERIVATIVES
DE60128100D1 (en) ANALGICAL DRUG
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
SE0101082D0 (en) Novel use
PE20010744A1 (en) USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL FOR THE TREATMENT OF OBESITY
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
DE60121048D1 (en) PYRAZINOi1'2 ': 1,6öPYRIDOi3,4-BöINDOLDERIVATE
ES2191908T3 (en) 4-AMINOPIRROL (3,2-D) PYRIMIDINS AS ANTAGONISTS OF THE NEUROPEPTIDE RECEPTOR.
SV2001000202A (en) USE OF (-) - 5-CETO-2-N, N-D1-N-PROPYLAMINE-TETRAHYDROTETHRALINE FOR THE TREATMENT OF PARKINSON'S EVIL
AR043016A2 (en) AN ELTIRIPTAN ANTIMIGRANIC COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING IT
UY26405A1 (en) METHOD FOR TREATING PARKINSON'S EVIL THROUGH THE ADMINISTRATION OF (-) - 5-CETO-2-N, N-D1-N-PROPYLAMINE-TETRAHYDROTETRALINE.